Cardiac Implants Market size is poised to cross USD 50 Billion by the end of 2035, growing at a CAGR of 8% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of cardiac implants was over USD 25 Billion. The major factor for the growth of the global cardiac implants market in the upcoming years is the rising prevalence of cardiovascular diseases and heart diseases among the global population owing to the rapid shift towards unhealthy lifestyles and consumption of junk. As per the World Health Organization (WHO), cardiovascular diseases are considered to be one of the major causes of death worldwide. Further, a recent report stated that approximately 17.9 million people across the world lost their lives in 2019 which is equivalent to 32% of the entire global deaths owing to growing cardiovascular diseases.
Apart from the aforementioned factors, one of the other major factors that are attributed to market growth is the rapid escalation of heart failure cases which is expected to positively influence the demand for cardiac implants around the world. Also, the surge in the number of heart attacks, heart strokes, and other chronic heart ailments is anticipated to bring lucrative growth opportunities for market growth during the forecast period. Moreover, the change in lifestyles such as unhealthy dietary patterns, high-stress levels, excessive alcohol consumption, increase in cigarette usage, and reduced physical activity has also propelled several heart disorders and is also estimated to boost the expansion of market growth in the next few years. The occurrence of lifestyle disorders such as diabetes and obesity is also forecasted to generate a demand for cardiac implants which in turn is expected to aid market growth. In addition to that, the growing geriatric population which is more prone to medical conditions along with significant improvements in the healthcare infrastructure is also contributing to the market growth. Additionally, the preference for minimally invasive surgeries and integration of artificial intelligence (AI) for advanced algorithms for early detection of heart disease, enhanced treatment of strokes, and faster diagnostic radiology capabilities are also estimated to create a positive outlook for the market. In addition to the other factors, the surge in the awareness levels about the numerous benefits of cardiac implants coupled with the recent advancements in the medical sector and increasing research and development (R&D) activities are offering favorable growth opportunities to market key players.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
8% |
|
Base Year Market Size (2022) |
USD 25 Billion |
|
Forecast Year Market Size (2035) |
USD 50 Billion |
|
Regional Scope |
|
The global cardiac implants market is segmented and analyzed for demand and supply by end-users into cardiology centers, clinics, hospitals, and others. Out of these, the hospitals segment is attributed to garner the most significant share in the market by the end of 2035. The major factor attributed to the expansion of the segment is the presence of specially trained medical professionals for the usage of cardiac implants and a high number of cardiologists in hospitals across the globe. Also, the high number of hospitals in the world is considered to be another factor for the increased utilization rate of cardiac implants in hospital settings. For instance, the Organization for Economic Co-Operation and Development (OECD) stated that the number of hospitals in the United Kingdom increased from 1,882 in 2015 to 1921 in 2020, whereas, in the United States it rose from 5,564 in 2015 to 6,090 in 2019. In addition, the trust factor associated with the hospitals for proper diagnosis and treatment coupled with favorable policies present in the hospitals is also another factor that is considered to bring growth opportunities for noteworthy revenue generation of the segment. Patients suffering from chronic diseases, cardiovascular disorders, and other lifestyle illnesses often visit hospitals for treatment procedures which in turn is expected to boost segment growth in the next few years.
The global cardiac implants market is also segmented and analyzed for demand and supply by application into acute myocardial infarction, myocardial ischemia, arrhythmias, congestive heart failures, and others. Out of these, the arrhythmias segment is projected to hold the largest share with a notable CAGR during the forecast period. The major factor for segment growth is the rising cases of arrhythmias and related diseases across the globe. For instance, in 2022, it was revealed that the prevalence of arrhythmias is found to be 2% to 5% in the world population. An unhealthy lifestyle and consumption of a poor diet is the reason behind the growth in the occurrence of arrhythmias.
Our in-depth analysis of the global cardiac implants market includes the following segments:
|
By Product |
|
|
By Material |
|
|
By Procedure |
|
|
By Application |
|
|
By End-User |
|
North America Market Forecast
The North American cardiac implants market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of arrhythmias, and other heart diseases in the region. For instance, around 12 million Americans are estimated to be diagnosed with atrial fibrillation by 2030. Further, the presence of a strong healthcare network in the region, along with the availability of a large pool of patients is also anticipated to contribute to the market growth in the region. In addition, the region's expanding healthcare industry and rising commercialization of medical equipment are also anticipated to boost market growth during the forecast period.
Asia Pacific Market Forecast
On the other hand, the Asia Pacific cardiac implants market is also attributed to holding a significant market share during the analysis period on the account of growing geriatric population in the region who are at higher risk of cardiovascular diseases. Also, the high prevalence rate of cardiovascular diseases, and other heart-related disorders among the population is expected to boost the expansion of market size in the region. Recent reports suggest that cardiovascular diseases were the leading cause of death in the Asia Pacific region taking up around 11 million lives in 2019, which is approximately 35% of the total death in the region.
Boston Scientific Corporation acquired clearance from the U.S. Food and Drug Administration (FDA) for its EMBOLD Fibered Detachable Coil that decreases the rate of peripheral vasculature blood flow.
BIOTRONIK, Inc. received approval of Renamic New, a software programmer for cardiac rhythm management devices, from the U.S. Food and Drug Administration (FDA).
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?